Nisa Investment Advisors LLC continued to hold its position in shares of Pharmerica Corporation (NYSE:PMC) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,774 shares of the company’s stock at the end of the second quarter. Nisa Investment Advisors LLC’s holdings in Pharmerica Corporation were worth $125,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in PMC. Parametric Portfolio Associates LLC increased its position in shares of Pharmerica Corporation by 3.4% in the first quarter. Parametric Portfolio Associates LLC now owns 73,850 shares of the company’s stock worth $1,728,000 after buying an additional 2,422 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of Pharmerica Corporation during the first quarter worth approximately $218,000. Comerica Bank boosted its stake in shares of Pharmerica Corporation by 17.1% in the first quarter. Comerica Bank now owns 38,381 shares of the company’s stock worth $912,000 after buying an additional 5,608 shares during the last quarter. US Bancorp DE boosted its stake in shares of Pharmerica Corporation by 41.3% in the first quarter. US Bancorp DE now owns 7,121 shares of the company’s stock worth $167,000 after buying an additional 2,081 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Pharmerica Corporation by 82.5% in the first quarter. First Trust Advisors LP now owns 102,282 shares of the company’s stock worth $2,393,000 after buying an additional 46,231 shares during the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.
Shares of Pharmerica Corporation (NYSE PMC) remained flat at $29.05 during midday trading on Friday. 178,286 shares of the stock were exchanged. Pharmerica Corporation has a one year low of $19.20 and a one year high of $29.10. The company has a market capitalization of $904.07 million, a P/E ratio of 39.36 and a beta of 0.92. The stock’s 50-day moving average price is $26.97 and its 200 day moving average price is $25.04.
Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 EPS for the quarter, hitting analysts’ consensus estimates of $0.47. The company had revenue of $592 million during the quarter, compared to analyst estimates of $592.96 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.47 earnings per share. Equities analysts expect that Pharmerica Corporation will post $1.92 earnings per share for the current year.
WARNING: “Pharmerica Corporation (PMC) Stake Maintained by Nisa Investment Advisors LLC” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/18/pharmerica-corporation-pmc-stake-maintained-by-nisa-investment-advisors-llc.html.
A number of brokerages recently commented on PMC. UBS AG reissued a “neutral” rating and issued a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. KeyCorp cut shares of Pharmerica Corporation to an “overweight” rating in a research note on Wednesday, August 2nd. Zacks Investment Research cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Barrington Research cut shares of Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Thursday, August 3rd. Finally, Credit Suisse Group cut shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Pharmerica Corporation presently has a consensus rating of “Hold” and an average price target of $28.83.
Pharmerica Corporation Company Profile
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
